Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Taiwan University Hospital |
---|---|
Information provided by: | National Taiwan University Hospital |
ClinicalTrials.gov Identifier: | NCT00304694 |
18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.
We propose to conduct a prospective study to evaluate therapeutic response using 18F-FDG PET before and after induction chemotherapy for locally advanced NPC patients.
Condition |
---|
Nasopharyngeal Cancer |
Study Type: | Observational |
Study Design: | Screening, Cross-Sectional, Convenience Sample, Prospective Study |
Official Title: | Whole-Body 18F-FDG PET in Evaluating Induction Chemotherapeutic Response for Locally Advanced Nasopharyngeal Cancer Patients and Correlating With Histopathology: a Prospective Study |
Estimated Enrollment: | 50 |
Study Start Date: | March 2006 |
In order to improve locoregional control and to eradicate micrometastases for patients with locally advanced nasopharyngeal carcinoma (NPC), induction chemotherapy followed by concurrent chemoradiotherapy has been the preferred therapeutic approach.Although it would be of great advantage to identify non-responder during or immediately after therapy to formulate an alternative treatment strategy, non-invasive methods for early evaluation of therapeutic response for advanced NPC patients have not been fully evaluated. Decrease of tumor volume in anatomical images and relief of symptoms in clinical follow-up have been used in many conventional approaches to evaluate the effectiveness of therapy. However, an effective therapy could very well have resulted in early subclinical alterations in tumor physiology and biochemistry. These alterations may have occurred long before changes in the tumor mass become apparent. Thus therapeutic effect may not be assessed accurately using the conventional anatomical imaging studies, such as CT and MRI.Recent studies have shown that 18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.We therefore propose to conduct a prospective study to evaluate therapeutic response using 18F-FDG PET before and after induction chemotherapy for locally advanced NPC patients.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ruoh-Fang Yen, MD, PhD | 886-2-23123456 ext 5581 | rfyen@ha.mc.ntu.edu.tw |
Taiwan | |
National Taiwan University Hospital | Recruiting |
Taipei, Taiwan, 10012 | |
Principal Investigator: Ruoh-Fang Yen, MD, PhD |
Principal Investigator: | Ruoh-Fang Yen, MD, PhD | National Taiwan University Hospital |
Study ID Numbers: | 940601 |
Study First Received: | March 16, 2006 |
Last Updated: | March 16, 2006 |
ClinicalTrials.gov Identifier: | NCT00304694 History of Changes |
Health Authority: | Taiwan: Department of Health |
NPC Induction chemotherapy Therapeutic response 18F-FDG PET |
Nasopharyngeal Carcinoma Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Head and Neck Neoplasms |
Pharyngeal Neoplasms Stomatognathic Diseases Pharyngeal Diseases Nasopharyngeal Neoplasms |
Neoplasms Otorhinolaryngologic Diseases Neoplasms by Site Otorhinolaryngologic Neoplasms Head and Neck Neoplasms |
Nasopharyngeal Diseases Pharyngeal Neoplasms Stomatognathic Diseases Pharyngeal Diseases Nasopharyngeal Neoplasms |